...ered that two microRNA (miRNA) molecules help cont...of B-cell chronic lymphocytic leukemia (B-CLL), th...r findings, published in the December 15 issue of ...ing as powerful regulators of gene expression in c... drug treatment, the investigators say. , In t...
...blem could be eliminated simply by dusting slag on...& Industry, the magazine of the SCI. , In the ...f damage annually. , Researcher David Cowen and...t applying slag to wheat growing in greenhouses ha...orporate the silica and express it as spiky struct...
... of plants to defend themselves by accumulating hi...me insects, and that such adaptation potentially e...ites may in turn evolve to deal with high levels o...zabeth Pilon-Smits of Colorado State University an...rnia, Berkeley, appear in the November 21st issue ...
Other Biology News:Pair of microRNA molecules controls major oncogene in most common leukemia 2New moth variety disarms plants guarded by selenium 2(Date:11/24/2009)... Health care employment grew by 29...ly one to show consistent growth during the U.S. r... remain in trouble, and health systems are coming ..., instead of just administrators. , ...e employment continued growing in October despite ...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- S...amp; Drug Administration (SFDA) has approved the,i...oral insulin project,(Nodlin), an innovative insul...l allows Biolaxy to initiate its first phase I cli...racteristic of high blood glucose and poor,metabol...
(Date:11/24/2009)..., TSX VENTURE: HTL , TORONTO, Nov. 24 /PRNews...), formerly Calotto Capital Inc., a leading provid...he stem cell research and fertility clinic markets... for the third quarter ended September 30, 2009. ,...46 million compared with $1.43 million in Q3 2008,...
(Date:11/24/2009)..., BOZEN, Italy, November 24 ... a new Canadian joint venture with a group of sele... company will operate under the,name Health Roboti...ort,Health Robotics, i.v. Room of the Future conce...ings i.v.STATION(TM), i.v.SOFT(TM), and OMM(TM).,H...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3...12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) to...e 3 clinical programs, Unit Dose Budesonide (UDB) ... treatment of migraine. For UDB, all,patients hav...itial Phase 3,clinical trial, and for MAP0004, the...in its initial Phase 3 clinical trial by the end o...
...of Schedule , , ST. LOUIS and RICHMOND, Calif., ... ) today announced it has reached a major producti...h Sigma-Aldrich Corporation (Nasdaq: SIAL ) to c...for research applications. The milestone triggers ...ng this production milestone more than one year ah...
...sset, Inc. (Nasdaq: VRUS ) announced today that ...reed with the FDA on the final design for a phase ...atitis C (HCV), slated to initiate in the first qu...8 is advancing into a large phase 2b trial," state...ical Officer. "R7128 is the most advanced nucleosi...
Other Biology Technology:MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 2Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5DNeasy Plant Mini Kit (250) from QIAGEN
...d Rocker, with 12" x 14" table; 115V 512500-00 VSR...20V. The VSR-50 Variable Speed Rocker is an essen...ovides a rhythmic side-to-side motion and its vari...nt. This makes it ideal for: gel staining/destaini...
Benzonase Nuclease HC, Purity > 90% from Novagen
... Plate is a 96-well ELISA-compatible plate (contai...r Monoclonal Antibody is immobilized by a method t... specifically recognizes the tail fiber protein of... a capacity of 10 9 phage per well and low non-sp...
Biology Products: